grant
Targeting DHX9 to trigger viral mimicry and immunotherapy responsiveness in Small Cell Lung Cancer (SCLC)
Organization RESEARCH INST OF FOX CHASE CAN CTRLocation PHILADELPHIA, UNITED STATESPosted 1 Aug 2024Deadline 31 Jul 2029
NIHUS FederalResearch GrantFY2025AblationAbscopal effectAnti-viral ResponseAntitumor ResponseBioavailabilityBiological AvailabilityCancer ModelCancer TreatmentCancerModelCancersCell BodyCell Communication and SignalingCell DeathCell SignalingCell SurvivalCell ViabilityCellsClinicalComplexDNADNA DamageDNA HelicasesDNA InjuryDNA ReplicationDNA SynthesisDNA Unwinding ProteinsDNA biosynthesisDNA unwinding enzymeDataDeoxyribonucleic AcidDouble-Stranded RNAElementsEnhancersEventGene TranscriptionGenetic EngineeringGenetic Engineering BiotechnologyGenetic Engineering Molecular BiologyGenetic TranscriptionGenome InstabilityGenome StabilityGenomic InstabilityGenomic StabilityGenomicsHybridsIFNImmune mediated therapyImmune responseImmunochemical ImmunologicImmunocompetentImmunologicImmunologicalImmunologicallyImmunologically Directed TherapyImmunologicsImmunotherapyIn VitroInnate Immune ResponseInnate ImmunityInterferonsIntracellular Communication and SignalingMaintenanceMalignant CellMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorMedicineMethodologyMiceMice MammalsModalityMurineMusNative ImmunityNatural ImmunityNon-Polyadenylated RNANon-Specific ImmunityNonspecific ImmunityNucleic AcidsOat cell carcinomaOralPathway interactionsPhysiologic AvailabilityPublic HealthRNARNA ExpressionRNA Gene ProductsRNA ProcessingRNA TransportRecombinant DNA TechnologyRegulationResistanceResolutionRibonucleic AcidRibonucleic Acid TransportRoleSignal TransductionSignal Transduction SystemsSignalingSmall Cell Lung CancerTestingTranscriptionTreatment outcomeTumor CellTumor ImmunityViralVirusabscopal activityabscopal responseanti-cancer immunotherapyanti-cancer therapyanti-tumor immune responseanti-tumor immunityanti-tumor responseanticancer immunotherapyantitumor immunitybiological signal transductioncancer cellcancer immunitycancer immunotherapycancer microenvironmentcancer therapycancer typecancer-directed therapycheck point blockadecheckpoint blockadedsRNAepigenetic therapygenetically engineeredhelicasehost responseimmune check point blockadeimmune checkpoint blockadeimmune competentimmune system responseimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenicimmunogenicityimmunoresponseimmunotherapy for cancerimmunotherapy of cancerimprovedin vivoinhibitorinnovateinnovationinnovativeknock-downknockdownlung cancer celllung oat cell carcinomalung small cell neuroendocrine carcinomamalignancymimeticsmimicrymouse modelmurine modelnecrocytosisneoplasm/cancerneoplastic cellnovelnucleic acid structureoat cell cancerpathwaypatient subclasspatient subclusterpatient subgroupspatient subpopulationspatient subsetspatient subtypesreplication stressresistance mechanismresistantresistant mechanismresolutionsresponsesmall cell lung carcinomasmall cell undifferentiated carcinomasmall molecular inhibitorsmall molecule inhibitorsocial rolesuccesstumortumor growthtumor microenvironment
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
PROJECT SUMMARY / ABSTRACT
Despite the impressive clinical success of Immune checkpoint blockade (ICB) therapy in cancer, therapy
resistance is common and only a small subset of patients mounts lasting antitumor responses, highlighting the
urgent need to identify strategies to overcome resistance and improve responsiveness to immunotherapy. Such…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click